دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Sex, gender, and the cost of neurological disorders
doi : 10.1016/S1474-4422(23)00120-5
Volume 22, Issue 5, May 2023, Page 367
New therapies for autoimmune myasthenia gravis
Jan Verschuuren
doi : 10.1016/S1474-4422(23)00125-4
Volume 22, Issue 5, May 2023, Pages 368-369
α-synuclein seed amplification and its uses in Parkinson's disease
*Daniela Berg, Christine Klein
doi : 10.1016/S1474-4422(23)00124-2
Volume 22, Issue 5, May 2023, Pages 369-371
Chronic inflammation: a potential target in tauopathies
Christina Ising, *Michael T Heneka
doi : 10.1016/S1474-4422(23)00116-3
Volume 22, Issue 5, May 2023, Pages 371-373
Optimising epilepsy surgery
*John S Duncan, Peter N Taylor
doi : 10.1016/S1474-4422(23)00082-0
Volume 22, Issue 5, May 2023, Pages 373-374
Application of diagnostic criteria for optic neuritis
*Yi Du, Wenjing Luo
doi : 10.1016/S1474-4422(23)00111-4
Volume 22, Issue 5, May 2023, Page 375
Application of diagnostic criteria for optic neuritis
Stefan Gingele†, Konstantin Fritz Jendretzky†, Anna Bajor, Sven G Meuth, *Thomas Skripuletz
doi : 10.1016/S1474-4422(23)00112-6
Volume 22, Issue 5, May 2023, Pages 375-376
Application of diagnostic criteria for optic neuritis – Authors' reply
Axel Petzold, Yaou Liu on behalf of the International Consortium on Optic Neuritis (ICON)
doi : 10.1016/S1474-4422(23)00110-2
Volume 22, Issue 5, May 2023, Pages 376-377
The hyperacute vestibular syndrome: ear or brain?
Diego Kaski, Nehzat Koohi, Salman Haider, Arvind Chandratheva, Robert Simister
doi : 10.1016/S1474-4422(23)00115-1
Volume 22, Issue 5, May 2023, Pages 377-378
Correction to Lancet Neurol 2023; 22: 209–17
doi : 10.1016/S1474-4422(23)00107-2
Volume 22, Issue 5, May 2023, Page e7
Correction to Lancet Neurol 2023; 22: 303–11
doi : 10.1016/S1474-4422(23)00119-9
Volume 22, Issue 5, May 2023, Page e7
Sex, gender, and the cost of neurological disorders
doi : 10.1016/S1474-4422(23)00120-5
Volume 22, Issue 5, May 2023, Page 367
Vera Bril: what if?
Adrian Burton
doi : 10.1016/S1474-4422(23)00121-7
Volume 22, Issue 5, May 2023, Page 379
New therapies for autoimmune myasthenia gravis
Jan Verschuuren
doi : 10.1016/S1474-4422(23)00125-4
Volume 22, Issue 5, May 2023, Pages 368-369
α-synuclein seed amplification and its uses in Parkinson's disease
*Daniela Berg, Christine Klein
doi : 10.1016/S1474-4422(23)00124-2
Volume 22, Issue 5, May 2023, Pages 369-371
An old hypersomnia
Andrew J Lees
doi : 10.1016/S1474-4422(23)00123-0
Volume 22, Issue 5, May 2023, Page 380
Chronic inflammation: a potential target in tauopathies
Christina Ising, *Michael T Heneka
doi : 10.1016/S1474-4422(23)00116-3
Volume 22, Issue 5, May 2023, Pages 371-373
Turin as a neuroscience cradle
Alessandro Vercelli
doi : 10.1016/S1474-4422(22)00474-4
Volume 22, Issue 5, May 2023, Page 381
Optimising epilepsy surgery
*John S Duncan, Peter N Taylor
doi : 10.1016/S1474-4422(23)00082-0
Volume 22, Issue 5, May 2023, Pages 373-374
It's all in the detail
Danielle Gash
doi : 10.1016/S1474-4422(22)00478-1
Volume 22, Issue 5, May 2023, Page 382
Application of diagnostic criteria for optic neuritis
*Yi Du, Wenjing Luo
doi : 10.1016/S1474-4422(23)00111-4
Volume 22, Issue 5, May 2023, Page 375
Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study
Vera Bril, Artur Drużdż, Julian Grosskreutz, Ali A Habib, Renato Mantegazza, Sabrina Sacconi, Kimiaki Utsugisawa, John Vissing, Tuan Vu, Marion Boehnlein, Ali Bozorg, Maryam Gayfieva, Bernhard Greve, Franz Woltering, Henry J Kaminski, on behalf of the MG0003 study team*
doi : 10.1016/S1474-4422(23)00077-7
Volume 22, Issue 5, May 2023, Pages 383-394
Application of diagnostic criteria for optic neuritis
Stefan Gingele†, Konstantin Fritz Jendretzky†, Anna Bajor, Sven G Meuth, *Thomas Skripuletz
doi : 10.1016/S1474-4422(23)00112-6
Volume 22, Issue 5, May 2023, Pages 375-376
Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study
James F Howard Jr, Saskia Bresch, Angela Genge, Channa Hewamadduma, John Hinton, Yessar Hussain, Raul Juntas-Morales, Henry J Kaminski, Angelina Maniaol, Renato Mantegazza, Masayuki Masuda, Kumaraswamy Sivakumar, Marek Śmiłowski, Kimiaki Utsugisawa, Tuan Vu, Michael D Weiss, Małgorzata Zajda, Babak Boroojerdi, Melissa Brock, Guillemette de la Borderie, Petra W Duda, Romana Lowcock, Mark Vanderkelen, M Isabel Leite and the RAISE Study Team*
doi : 10.1016/S1474-4422(23)00080-7
Volume 22, Issue 5, May 2023, Pages 395-406
Application of diagnostic criteria for optic neuritis – Authors' reply
Axel Petzold, Yaou Liu on behalf of the International Consortium on Optic Neuritis (ICON)
doi : 10.1016/S1474-4422(23)00110-2
Volume 22, Issue 5, May 2023, Pages 376-377
Assessment of heterogeneity among participants in the Parkinson's Progression Markers Initiative cohort using α-synuclein seed amplification: a cross-sectional study
Andrew Siderowf*, Luis Concha-Marambio*, David-Erick Lafontant, Carly M Farris, Yihua Ma, Paula A Urenia, Hieu Nguyen, Roy N Alcalay, Lana M Chahine, Tatiana Foroud, Douglas Galasko, Karl Kieburtz, Kalpana Merchant, Brit Mollenhauer, Kathleen L Poston, John Seibyl, Tanya Simuni, Caroline M Tanner, Daniel Weintraub, Aleksandar Videnovic, Seung Ho Choi, Ryan Kurth, Chelsea Caspell-Garcia, Christopher S Coffey, Mark Frasier, Luis M A Oliveira, Samantha J Hutten, Todd Sherer, Kenneth Marek, Claudio Soto, on behalf of the Parkinson’s Progression Markers Initiativeâ€
doi : 10.1016/S1474-4422(23)00109-6
Volume 22, Issue 5, May 2023, Pages 407-417
The hyperacute vestibular syndrome: ear or brain?
Diego Kaski, Nehzat Koohi, Salman Haider, Arvind Chandratheva, Robert Simister
doi : 10.1016/S1474-4422(23)00115-1
Volume 22, Issue 5, May 2023, Pages 377-378
Thrombolysis for acute ischaemic stroke: current status and future perspectives
Georgios Tsivgoulis, Aristeidis H Katsanos, Else Charlotte Sandset, Guillaume Turc, Thanh N Nguyen, Andrew Bivard, Urs Fischer, Pooja Khatri
doi : 10.1016/S1474-4422(22)00519-1
Volume 22, Issue 5, May 2023, Pages 418-429
Correction to Lancet Neurol 2023; 22: 209–17
doi : 10.1016/S1474-4422(23)00107-2
Volume 22, Issue 5, May 2023, Page e7
Chronic effects of inflammation on tauopathies
Connor Langworth-Green, Saisha Patel, Zane Jaunmuktane, Edwin Jabbari, Huw Morris, Maria Thom, Andrew Lees, John Hardy, Michael Zandi, Karen Duff
doi : 10.1016/S1474-4422(23)00038-8
Volume 22, Issue 5, May 2023, Pages 430-442
Correction to Lancet Neurol 2023; 22: 303–11
doi : 10.1016/S1474-4422(23)00119-9
Volume 22, Issue 5, May 2023, Page e7
Personalised virtual brain models in epilepsy
Viktor Jirsa, Huifang Wang, Paul Triebkorn, Meysam Hashemi, Jayant Jha, Jorge Gonzalez-Martinez, Maxime Guye, Julia Makhalova, Fabrice Bartolomei
doi : 10.1016/S1474-4422(23)00008-X
Volume 22, Issue 5, May 2023, Pages 443-454
Vera Bril: what if?
Adrian Burton
doi : 10.1016/S1474-4422(23)00121-7
Volume 22, Issue 5, May 2023, Page 379
An old hypersomnia
Andrew J Lees
doi : 10.1016/S1474-4422(23)00123-0
Volume 22, Issue 5, May 2023, Page 380
Turin as a neuroscience cradle
Alessandro Vercelli
doi : 10.1016/S1474-4422(22)00474-4
Volume 22, Issue 5, May 2023, Page 381
It's all in the detail
Danielle Gash
doi : 10.1016/S1474-4422(22)00478-1
Volume 22, Issue 5, May 2023, Page 382
Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study
Vera Bril, Artur Drużdż, Julian Grosskreutz, Ali A Habib, Renato Mantegazza, Sabrina Sacconi, Kimiaki Utsugisawa, John Vissing, Tuan Vu, Marion Boehnlein, Ali Bozorg, Maryam Gayfieva, Bernhard Greve, Franz Woltering, Henry J Kaminski, on behalf of the MG0003 study team*
doi : 10.1016/S1474-4422(23)00077-7
Volume 22, Issue 5, May 2023, Pages 383-394
Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study
James F Howard Jr, Saskia Bresch, Angela Genge, Channa Hewamadduma, John Hinton, Yessar Hussain, Raul Juntas-Morales, Henry J Kaminski, Angelina Maniaol, Renato Mantegazza, Masayuki Masuda, Kumaraswamy Sivakumar, Marek Śmiłowski, Kimiaki Utsugisawa, Tuan Vu, Michael D Weiss, Małgorzata Zajda, Babak Boroojerdi, Melissa Brock, Guillemette de la Borderie, Petra W Duda, Romana Lowcock, Mark Vanderkelen, M Isabel Leite and the RAISE Study Team*
doi : 10.1016/S1474-4422(23)00080-7
Volume 22, Issue 5, May 2023, Pages 395-406
Assessment of heterogeneity among participants in the Parkinson's Progression Markers Initiative cohort using α-synuclein seed amplification: a cross-sectional study
Andrew Siderowf*, Luis Concha-Marambio*, David-Erick Lafontant, Carly M Farris, Yihua Ma, Paula A Urenia, Hieu Nguyen, Roy N Alcalay, Lana M Chahine, Tatiana Foroud, Douglas Galasko, Karl Kieburtz, Kalpana Merchant, Brit Mollenhauer, Kathleen L Poston, John Seibyl, Tanya Simuni, Caroline M Tanner, Daniel Weintraub, Aleksandar Videnovic, Seung Ho Choi, Ryan Kurth, Chelsea Caspell-Garcia, Christopher S Coffey, Mark Frasier, Luis M A Oliveira, Samantha J Hutten, Todd Sherer, Kenneth Marek, Claudio Soto, on behalf of the Parkinson’s Progression Markers Initiativeâ€
doi : 10.1016/S1474-4422(23)00109-6
Volume 22, Issue 5, May 2023, Pages 407-417
Thrombolysis for acute ischaemic stroke: current status and future perspectives
Georgios Tsivgoulis, Aristeidis H Katsanos, Else Charlotte Sandset, Guillaume Turc, Thanh N Nguyen, Andrew Bivard, Urs Fischer, Pooja Khatri
doi : 10.1016/S1474-4422(22)00519-1
Volume 22, Issue 5, May 2023, Pages 418-429
Chronic effects of inflammation on tauopathies
Connor Langworth-Green, Saisha Patel, Zane Jaunmuktane, Edwin Jabbari, Huw Morris, Maria Thom, Andrew Lees, John Hardy, Michael Zandi, Karen Duff
doi : 10.1016/S1474-4422(23)00038-8
Volume 22, Issue 5, May 2023, Pages 430-442
Personalised virtual brain models in epilepsy
Viktor Jirsa, Huifang Wang, Paul Triebkorn, Meysam Hashemi, Jayant Jha, Jorge Gonzalez-Martinez, Maxime Guye, Julia Makhalova, Fabrice Bartolomei
doi : 10.1016/S1474-4422(23)00008-X
Volume 22, Issue 5, May 2023, Pages 443-454
Sex, gender, and the cost of neurological disorders
doi : 10.1016/S1474-4422(23)00120-5
Volume 22, Issue 5, May 2023, Page 367
New therapies for autoimmune myasthenia gravis
Jan Verschuuren
doi : 10.1016/S1474-4422(23)00125-4
Volume 22, Issue 5, May 2023, Pages 368-369
α-synuclein seed amplification and its uses in Parkinson's disease
*Daniela Berg, Christine Klein
doi : 10.1016/S1474-4422(23)00124-2
Volume 22, Issue 5, May 2023, Pages 369-371
Chronic inflammation: a potential target in tauopathies
Christina Ising, *Michael T Heneka
doi : 10.1016/S1474-4422(23)00116-3
Volume 22, Issue 5, May 2023, Pages 371-373
Optimising epilepsy surgery
*John S Duncan, Peter N Taylor
doi : 10.1016/S1474-4422(23)00082-0
Volume 22, Issue 5, May 2023, Pages 373-374
Application of diagnostic criteria for optic neuritis
*Yi Du, Wenjing Luo
doi : 10.1016/S1474-4422(23)00111-4
Volume 22, Issue 5, May 2023, Page 375
Application of diagnostic criteria for optic neuritis
Stefan Gingele†, Konstantin Fritz Jendretzky†, Anna Bajor, Sven G Meuth, *Thomas Skripuletz
doi : 10.1016/S1474-4422(23)00112-6
Volume 22, Issue 5, May 2023, Pages 375-376
Application of diagnostic criteria for optic neuritis – Authors' reply
Axel Petzold, Yaou Liu on behalf of the International Consortium on Optic Neuritis (ICON)
doi : 10.1016/S1474-4422(23)00110-2
Volume 22, Issue 5, May 2023, Pages 376-377
The hyperacute vestibular syndrome: ear or brain?
Diego Kaski, Nehzat Koohi, Salman Haider, Arvind Chandratheva, Robert Simister
doi : 10.1016/S1474-4422(23)00115-1
Volume 22, Issue 5, May 2023, Pages 377-378
Correction to Lancet Neurol 2023; 22: 209–17
doi : 10.1016/S1474-4422(23)00107-2
Volume 22, Issue 5, May 2023, Page e7
Correction to Lancet Neurol 2023; 22: 303–11
doi : 10.1016/S1474-4422(23)00119-9
Volume 22, Issue 5, May 2023, Page e7
Vera Bril: what if?
Adrian Burton
doi : 10.1016/S1474-4422(23)00121-7
Volume 22, Issue 5, May 2023, Page 379
An old hypersomnia
Andrew J Lees
doi : 10.1016/S1474-4422(23)00123-0
Volume 22, Issue 5, May 2023, Page 380
Turin as a neuroscience cradle
Alessandro Vercelli
doi : 10.1016/S1474-4422(22)00474-4
Volume 22, Issue 5, May 2023, Page 381
It's all in the detail
Danielle Gash
doi : 10.1016/S1474-4422(22)00478-1
Volume 22, Issue 5, May 2023, Page 382
Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study
Vera Bril, Artur Drużdż, Julian Grosskreutz, Ali A Habib, Renato Mantegazza, Sabrina Sacconi, Kimiaki Utsugisawa, John Vissing, Tuan Vu, Marion Boehnlein, Ali Bozorg, Maryam Gayfieva, Bernhard Greve, Franz Woltering, Henry J Kaminski, on behalf of the MG0003 study team*
doi : 10.1016/S1474-4422(23)00077-7
Volume 22, Issue 5, May 2023, Pages 383-394
Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study
James F Howard Jr, Saskia Bresch, Angela Genge, Channa Hewamadduma, John Hinton, Yessar Hussain, Raul Juntas-Morales, Henry J Kaminski, Angelina Maniaol, Renato Mantegazza, Masayuki Masuda, Kumaraswamy Sivakumar, Marek Śmiłowski, Kimiaki Utsugisawa, Tuan Vu, Michael D Weiss, Małgorzata Zajda, Babak Boroojerdi, Melissa Brock, Guillemette de la Borderie, Petra W Duda, Romana Lowcock, Mark Vanderkelen, M Isabel Leite and the RAISE Study Team*
doi : 10.1016/S1474-4422(23)00080-7
Volume 22, Issue 5, May 2023, Pages 395-406
Assessment of heterogeneity among participants in the Parkinson's Progression Markers Initiative cohort using α-synuclein seed amplification: a cross-sectional study
Andrew Siderowf*, Luis Concha-Marambio*, David-Erick Lafontant, Carly M Farris, Yihua Ma, Paula A Urenia, Hieu Nguyen, Roy N Alcalay, Lana M Chahine, Tatiana Foroud, Douglas Galasko, Karl Kieburtz, Kalpana Merchant, Brit Mollenhauer, Kathleen L Poston, John Seibyl, Tanya Simuni, Caroline M Tanner, Daniel Weintraub, Aleksandar Videnovic, Seung Ho Choi, Ryan Kurth, Chelsea Caspell-Garcia, Christopher S Coffey, Mark Frasier, Luis M A Oliveira, Samantha J Hutten, Todd Sherer, Kenneth Marek, Claudio Soto, on behalf of the Parkinson’s Progression Markers Initiativeâ€
doi : 10.1016/S1474-4422(23)00109-6
Volume 22, Issue 5, May 2023, Pages 407-417
Thrombolysis for acute ischaemic stroke: current status and future perspectives
Georgios Tsivgoulis, Aristeidis H Katsanos, Else Charlotte Sandset, Guillaume Turc, Thanh N Nguyen, Andrew Bivard, Urs Fischer, Pooja Khatri
doi : 10.1016/S1474-4422(22)00519-1
Volume 22, Issue 5, May 2023, Pages 418-429
Chronic effects of inflammation on tauopathies
Connor Langworth-Green, Saisha Patel, Zane Jaunmuktane, Edwin Jabbari, Huw Morris, Maria Thom, Andrew Lees, John Hardy, Michael Zandi, Karen Duff
doi : 10.1016/S1474-4422(23)00038-8
Volume 22, Issue 5, May 2023, Pages 430-442
Personalised virtual brain models in epilepsy
Viktor Jirsa, Huifang Wang, Paul Triebkorn, Meysam Hashemi, Jayant Jha, Jorge Gonzalez-Martinez, Maxime Guye, Julia Makhalova, Fabrice Bartolomei
doi : 10.1016/S1474-4422(23)00008-X
Volume 22, Issue 5, May 2023, Pages 443-454
